GDC-0980 - CAS# 1032754-93-0 Catalog No.:M10683-10 Marbofloxacin treatment at the therapeutic

Marbofloxacin treatment at the therapeutic dose does not eliminate M

with an IC50 of ~50 nM with either substrate

Chemical Name: 4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol

It was originated by Roche but as of 2008 is sold by Meda AB under the trade name Mobiflex

Smiles: CN1CCC[C@@H]1CCO[C@](C)(C1C=CC=CC=1)C1C=CC(Cl)=CC=1

GDC-0980 - CAS# 1032754-93-0 Catalog No.:M10683-10 Marbofloxacin treatment at the therapeuticApitolisib, also known as GDC 0980 and RG7422; or GNE390, is a dual PI3 kinase mTOR inhibitor, is also a n orally available agent targeting phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinase in the PI3K mTOR signaling pathway, with potential antineoplastic activity. PI3K mTOR kinase inhibitor GDC 0980 inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition of cancer